The Things You Have To Tell Yourself If You’re A Donald

New Post Public Reply Private Reply Replies (0) Message Board

Jul 25, 2016 at 7:02 PM

Quote:

The Things You Have To Tell Yourself If You’re A Donald Trump Supporter

By Sean Colarossi on Mon, Jul 25th, 2016 at 6:12 pm

"It's okay – Congress will stop him if he tries to do anything insane"

It’s not easy supporting Donald Trump.

I don’t say that out of experience – I certainly don’t support one of the most unqualified and unstable candidates to ever seek the presidency – but I say it because the list of reasons people have for supporting Donald Trump is mind-boggling.

When broken down, these reasons unravel quickly.

He’ll surround himself with people much smarter and more level-headed than he is.

If you bring up the fact that Donald Trump is erratic, childish, reckless and doesn’t really know much (or care to) about foreign or domestic policy, the defense you’ll hear from the diehard Trumpites is that he will surround himself with people that know better.

Don’t worry about Trump having access to the nuclear codes, they say, because those around him will actually be the folks in charge.

Let me get this straight: Trump is so irresponsible that we shouldn’t trust him to be commander-in-chief, but we should trust him to surround himself with the right people?

Not to mention the fact that, when we cast our votes in November, we are voting for the candidate at the top of the ticket – not some nameless list of advisers that will supposedly keep the president in line.

This decades-old video clip shows who Trump really is.
http://www.politicususa.com/2016/07/25/donald...orter.html

There have been no shortage of inflammatory comments and dangerous policy proposals put forward by Donald Trump throughout this campaign. He has insulted minority groups, proposed barring an entire religion from entering the country, and mocked a reporter with a disability – to name only a few.

Ask a Trump supporter about these things and they’ll somehow work their way to blaming the media for it. It’s not fair to characterize him based on what he has said and proposed in this campaign, you’ll be told.

Instead, they’ll show you some decades-old video clip of Donald Trump acting semi-normal and even somewhat appealing in an interview with Oprah. They’ll say that is the real Trump.

So that must mean Trump is either pretending to be a buffoonish bigot now or he really is one. Neither of those options should be acceptable to voters.

If he’s elected, he won’t really do what he has promised to.

The big wall on the Mexican border? A sweeping ban of Muslims? Bombing innocent family members of terrorists? Torturing our enemies?

These ideas range from ridiculous to offensive to illegal, but it’s okay because Trump supporters truly believe he won’t really do anything of those things if he’s elected president. It’s essentially just for show, and they’re okay with that.

So either Trump is lying to win votes or he really will act on the promises he’s made in this campaign. Again, neither should be acceptable.

It’s okay – Congress will stop him if he tries to do anything insane.

Trump supporters have become huge lovers of our system of checks and balances, because you have to be in order to support a man who can’t be trusted with any level of power.

It’s okay that the GOP nominee is unstable – Congress won’t let him do anything too crazy, the argument goes.

It’s sort of like leaving a toddler and a gun in the same room and claiming that everything will be okay because the little tike doesn’t know how to pull the trigger.

All of these silly reasons speak volumes about the man the Republican Party has nominated for president, and they only underscore just how important it is to keep him out of the White House.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

NARUTO Card Game Set for June 2027 Global Launch

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...